DFTX Company Profile and Key Details

DFTX has shown sold momentum, gaining 20.89% over the past week and 22.93% over the past quarter, though year-to-date performance is up 25.32%. Short-term trend indicators are bearishly aligned (SMA20 0.97%, SMA50 11.63%, SMA200 53.73%). The stock’s 14-day RSI is 55.31 (neutral), while the ATR of 1.02 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -7.54% below its high and over 267.87% above its low. Average 10-day trading volume of 4.76 million shares is significantly above the 3-month average of 2.23 million, indicating heightened recent market interest.

Definium Therapeutics, Inc. generated EPS of -$1.97 over the past year. Five-year average earnings growth is 12.11%. Wall Street analysts project EPS growth of -0.05% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 7 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $70.00 to $25.00. The high target offers 90.89% upside. The low target suggests -31.82% downside. The mean target is $42.17. This offers 15.0% upside. Definium Therapeutics, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 07, 2026, missed forecasts by 44.27%. The prior quarter beat by 5.44%. Over the last six quarters, Apple has recorded several small beats. These include 24.24% in March 06, 2025.

Definium Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.89. This means the shares are trading above this model’s fair value.

Definium Therapeutics, Inc. (NASDAQ:DFTX) closed at $36.67 USD, gaining $12.19 (49.80%) from the previous close of $24.48. The stock is currently mid-range between its 52-week high and low $12.88 and $38.69. With a market capitalization of about $4.00 billion, Definium Therapeutics, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~2.38). Key stats such as the average daily volume over the past year has been around 3.36 million shares, trading with heavier-than-usual volume. Headquartered in New York, NY, Definium Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Robert Barrow, the company employs approximately 74 people and listed since November 15, 2016. Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders.

Definium Therapeutics, Inc. (NASDAQ:DFTX) shares are up 25.32% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Definium Therapeutics, Inc. trading at a premium to the broader market with a P/E of -14.35. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $42.17, suggesting 15.0% upside. Our AI forecast model points to short-term strength (3.19% over two weeks), a medium-term rise (52.85% over three months), and a longer-term gain (45.62% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Definium Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 3.19%, with price expected at $37.84 by July 06, 2026, within a range of $36.83 to $38.83 3-Month Outlook: Projected rise of 52.85%, reaching $56.05 by September 16, 2026, with a range of $55.86 to $56.23. 1-Year Outlook: Projected gain of 45.62%, with price at $53.40 by June 22, 2027, within a range of $53.22 to $53.58.

Definium Therapeutics, Inc. trades at a P/E ratio of -14.35, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 13.99 reflecting a rich premium to book value. The P/FCF stands at -27.23, also below market averages. Compared to sector medians, Definium Therapeutics, Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.